Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$100.40 ▲ +3.36
(+3.46%)
MKT CAP: $6.31B • VOL: 1.17M
52W L $16 52W H $104
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$84
MEDIAN
$112
MEAN
$114
HIGH
$137
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KOD TAPE
KOD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $121.48 | $115.46 | 2025-02-14 | $91.36 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $126.50 | $118.47 | 2025-02-06 | $94.38 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $114.46 | $110.44 | 2025-01-29 | $96.38 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $102.41 | — | 2025-01-17 | $98.39 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $88.35 | $95.38 | 2025-01-09 | $89.36 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $119.48 | $104.42 | 2024-12-18 | $87.35 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $97.39 | $101.40 | 2024-12-04 | $93.37 | -4.3% | 48% | C |